rHSA / Protgen - LARVOL DELTA

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites (clinicaltrials.gov) - P2/3 | N=390 | Completed | Sponsor: Protgen Ltd | Not yet recruiting ➔ Completed | Trial primary completion date: Jan 2025 ➔ May 2025

Trial completion • Trial primary completion date • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

To evaluate the safety and preliminary efficacy of recombinant human serum albumin injection in the treatment of mild to moderate Alzheimer's disease (ChiCTR) - P=N/A | N=30 | Recruiting | Sponsor: Shanghai Mental Health Center,; Shenzhen Protgen Ltd.

New trial • Alzheimer's Disease • CNS Disorders

A randomized, double-blind, parallel grouping phase II/III clinical trial to evaluate the efficacy and safety of recombinant human serum albumin versus human serum albumin in patients with cirrhosis and ascites(Phase III) (ChiCTR) - P3 | N=388 | Not yet recruiting | Sponsor: Beijing Friendship Hospital, Capital Medical University; Shenzhen Protgen Ltd.

New P3 trial • Fibrosis • Hepatology • Immunology

Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites (clinicaltrials.gov) - P2/3 | N=388 | Not yet recruiting | Sponsor: Protgen Ltd

New P2/3 trial • Fibrosis • Hepatology • Immunology • Liver Cirrhosis